These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 28494529

  • 1. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG, Boutari C, Stavropoulos K, Anagnostis P, Imprialos KP, Doumas M, Karagiannis A.
    Curr Vasc Pharmacol; 2018 Jun; 16(3):246-253. PubMed ID: 28676019
    [Abstract] [Full Text] [Related]

  • 4. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Sugimoto K, Inui H, Fukusato T.
    World J Gastroenterol; 2015 Apr 07; 21(13):3777-85. PubMed ID: 25852263
    [Abstract] [Full Text] [Related]

  • 5. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE, Rinella ME.
    Dig Dis Sci; 2016 May 07; 61(5):1387-97. PubMed ID: 26942734
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K, Stavropoulos K, Bouloukou S, Kerpiniotis G, Karagiannis A, Doumas M.
    Curr Vasc Pharmacol; 2018 May 07; 16(3):276-288. PubMed ID: 28676020
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
    Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L.
    Aliment Pharmacol Ther; 2014 Jan 07; 39(1):3-14. PubMed ID: 24206433
    [Abstract] [Full Text] [Related]

  • 11. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K.
    Diabetologia; 2016 Jun 07; 59(6):1112-20. PubMed ID: 27101131
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
    Iogna Prat L, Tsochatzis EA.
    Hormones (Athens); 2018 Jun 07; 17(2):219-229. PubMed ID: 29858843
    [Abstract] [Full Text] [Related]

  • 14. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015 Jun 07; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS.
    Metab Syndr Relat Disord; 2016 Nov 07; 14(9):417-430. PubMed ID: 27710160
    [Abstract] [Full Text] [Related]

  • 16. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
    Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K.
    J Clin Endocrinol Metab; 2017 Aug 01; 102(8):2950-2961. PubMed ID: 28575232
    [Abstract] [Full Text] [Related]

  • 17. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan 01; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 18. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H, Dufour JF.
    Liver Int; 2017 May 01; 37(5):634-647. PubMed ID: 27727520
    [Abstract] [Full Text] [Related]

  • 19. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A.
    Mol Metab; 2021 Aug 01; 50():101049. PubMed ID: 32673798
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.